MetaCap

Assembly Biosciences (ASMB) vs CytomX Therapeutics (CTMX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Assembly Biosciences (ASMB) has outperformed CytomX Therapeutics (CTMX) over the past year, losing 42.4% versus a loss of 47.7%. Over five years, ASMB leads with a -21.3% price change compared with -69.9% for CTMX. Assembly Biosciences is the larger company by market cap ($454.4 million vs $442.5 million), about 1.0 times the size.

Assembly Biosciences converts more of its revenue into profit, with a net margin of -8.5% versus -22.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ASMB-42.36%CTMX-47.68%
+80%+11%-58%
Nov 21, 20251 yearNov 20, 2026
ASMB-19.60%CTMX-72.34%
+46%-27%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ASMB versus CTMX key metrics
MetricASMBCTMX
Share price$22.19$2.03
Market cap$454.39M$442.55M
1-day change-1.38%-0.98%
YTD return-34.75%-52.35%
1-year return-42.36%-47.68%
5-year return-21.31%-69.93%
P/E ratio (TTM)29.59—
EPS (TTM)$0.75$-0.51
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$72.30M$76.20M
Revenue growth (YoY)+153.52%-44.82%
Net income (latest FY)$-6.12M$-17.37M
Operating margin-16.76%-29.35%
Net margin-8.47%-22.79%
52-week high$39.65$8.21
52-week low$19.20$1.87
Distance from 52-week high-44.04%-75.27%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+130.73%+509.85%
Average volume309.38K4.27M
Shares outstanding20.48M218.00M
Employees7369
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Assembly Biosciences is more profitable, keeping -8.5 cents of every revenue dollar as net income versus -22.8 cents for CytomX Therapeutics.
  • Assembly Biosciences grew revenue faster in its latest fiscal year (+153.52% vs -44.82%).

About Assembly Biosciences

ASMB stock →

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.

Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees

About CytomX Therapeutics

CTMX stock →

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment.

Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees

ASMB vs CTMX FAQ

Which is bigger, Assembly Biosciences or CytomX Therapeutics?

Assembly Biosciences (ASMB) is larger, with a market capitalization of $454.39M compared with $442.55M for CytomX Therapeutics (CTMX).

Which stock has performed better over the past year, ASMB or CTMX?

ASMB returned -42.36% over the past 12 months, compared with -47.68% for CTMX (price return, excluding dividends). Past performance does not predict future results.

Are Assembly Biosciences and CytomX Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons